Cilostazol and freedom from amputation after lower extremity revascularization

Journal of Vascular Surgery

Volumn 61, Issue 4, 2015, Pages 960-964

  Neel, J David ^a   Kruse, Robin L ^a   Dombrovskiy, Viktor Y ^b   Vogel, Todd R ^a  

^a University of Missouri   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CILOSTAZOL; ANTITHROMBOCYTIC AGENT; TETRAZOLE DERIVATIVE; VASODILATOR AGENT;

ACUTE KIDNEY FAILURE; AGED; ATHEROSCLEROSIS; COMORBIDITY; CONFERENCE PAPER; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG UTILIZATION; ENDOVASCULAR SURGERY; ETHNICITY; FEMALE; GANGRENE; HEART DISEASE; HEART INFARCTION; HEMATOMA; HUMAN; INTERMITTENT CLAUDICATION; KIDNEY FAILURE; LEG AMPUTATION; LEG PAIN; LEG REVASCULARIZATION; LEG ULCER; LIMB SALVAGE; MAJOR CLINICAL STUDY; MALE; MEDICARE; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PNEUMONIA; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RACE DIFFERENCE; RESPIRATORY TRACT DISEASE; SEX DIFFERENCE; SURGICAL INFECTION; VERY ELDERLY; ADVERSE EFFECTS; AMPUTATION; CHI SQUARE DISTRIBUTION; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; KAPLAN MEIER METHOD; LEG; MORTALITY; MULTIVARIATE ANALYSIS; PERIPHERAL ARTERIAL DISEASE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; UNITED STATES; VASCULARIZATION;

AGED; AGED, 80 AND OVER; AMPUTATION; CHI-SQUARE DISTRIBUTION; COMORBIDITY; DISEASE-FREE SURVIVAL; ENDOVASCULAR PROCEDURES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIMB SALVAGE; LOGISTIC MODELS; LOWER EXTREMITY; MALE; MEDICARE; MULTIVARIATE ANALYSIS; ODDS RATIO; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VASODILATOR AGENTS;

EID: 84925439844     PISSN: 07415214     EISSN: 10976809     Source Type: Journal    
DOI: 10.1016/j.jvs.2014.11.067     Document Type: Conference Paper

References (16)

1. W. Rosamond, K. Flegal, K. Furie, A. Go, K. Greenlund, and N. Haase Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 117 2008 e25 146
2. A.T. Hirsch, Z.J. Haskal, N.R. Hertzer, C.W. Bakal, M.A. Creager, and J.L. Halperin ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation Circulation 113 2006 e463 654
3. C. Lee, and P.R. Nelson Effect of cilostazol prescribed in a pragmatic treatment program for intermittent claudication Vasc Endovasc Surg 48 2014 224 229
4. Y. Kimura, T. Tani, T. Kanbe, and K. Watanabe Effect of cilostazol on platelet aggregation and experimental thrombosis Arzneimittelforschung 35 1985 1144 1149
5. J.S. Douglas Jr., D.R. Holmes Jr., D.J. Kereiakes, C.L. Grines, E. Block, and Z.M. Ghazzal Coronary stent restenosis in patients treated with cilostazol Circulation 112 2005 2826 2832
6. S.W. Lee, S.W. Park, Y.H. Kim, S.C. Yun, D.W. Park, and C.W. Lee A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial J Am Coll Cardiol 57 2011 1264 1270
7. E. Tsuchikane, A. Fukuhara, T. Kobayashi, M. Kirino, K. Yamasaki, and T. Kobayashi Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty Circulation 100 1999 21 26
8. C.J. Warner, S.W. Greaves, R.J. Larson, D.H. Stone, R.J. Powell, and D.B. Walsh Cilostazol is associated with improved outcomes after peripheral endovascular interventions J Vasc Surg 59 2014 1607 1614
9. O. Iida, S. Nanto, M. Uematsu, T. Morozumi, J. Kotani, and M. Awata Cilostazol reduces target lesion revascularization after percutaneous transluminal angioplasty in the femoropopliteal artery Circ J 69 2005 1256 1259
10. S.R. Money, J.A. Herd, J.L. Isaacsohn, M. Davidson, B. Cutler, and J. Heckman Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease J Vasc Surg 27 1998 267 274 discussion: 274-5
11. J. Shalhoub, A.H. Davies, and I.J. Franklin Cilostazol may improve outcome in critical limb ischemia Int Angiol 28 2009 363 366
12. Y. Soga, O. Iida, D. Kawasaki, K. Hirano, T. Yamaoka, and K. Suzuki Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia Eur J Vasc Endovasc Surg 44 2012 577 581
13. D.J. Angiolillo, P. Capranzano, J.L. Ferreiro, M. Ueno, D. Capodanno, and K. Dharmashankar Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy Thromb Haemost 106 2011 253 262
14. T. Uchikawa, T. Murakami, and H. Furukawa Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus Arzneimittelforschung 42 1992 322 324
15. M.E. O'Donnell, S.A. Badger, M.A. Sharif, R.R. Makar, I.S. Young, and B. Lee The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease Vasc Endovasc Surg 43 2009 132 143
16. H. Ishii, Y. Kumada, T. Toriyama, T. Aoyama, H. Takahashi, and S. Yamada Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease Clin J Am Soc Nephrol 3 2008 1034 1040